Tirzepatide is a once-weekly weight loss injection developed by Eli Lilly, now available for medical weight management in Singapore. Classified as a dual agonist, tirzepatide acts on both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This mechanism is distinct from traditional single-pathway treatments.
The medication is administered by subcutaneous injection, with a dosing protocol that typically ranges from 2.5mg to 15mg once weekly. Clinical trials have shown that tirzepatide can support significant weight reduction when prescribed as part of a doctor-supervised program.
This page provides a detailed overview of tirzepatide dual agonist weekly weight loss injections in Singapore, including its mechanism of action, clinical evidence, safety considerations, dosing, and key information for individuals considering this treatment.
Tirzepatide dual agonist injection is a prescription medication used for medical weight management in Singapore.
Unlike earlier medications that act only on GLP-1 receptors, tirzepatide targets both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors.
This dual mechanism provides a different approach to appetite regulation and metabolic control compared to single-pathway treatments.
Tirzepatide is a once-weekly injectable medication for adults with obesity or overweight. Its dual agonist profile means it stimulates both GIP and GLP-1 receptors, which are hormones involved in appetite regulation and glucose metabolism.
Tirzepatide was developed by Eli Lilly to offer an additional option for chronic weight management.
GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) are incretin hormones naturally produced in the gut in response to food intake. These hormones play essential roles in regulating blood sugar, appetite, and energy balance.
When food is consumed, both GIP and GLP-1 are released and signal to the pancreas to increase insulin secretion while suppressing glucagon release. This process helps to maintain stable blood glucose levels, particularly after meals.
Beyond their effects on insulin and glucagon, these hormones also communicate with the brain to promote satiety and reduce overall food intake.
GLP-1 receptor agonists, which have been used for several years in medical weight management, act specifically on GLP-1 receptors. They increase feelings of fullness, delay gastric emptying, and can lead to reduced calorie consumption.
However, tirzepatide’s dual agonist design means it also activates GIP receptors in addition to GLP-1 receptors.
The inclusion of GIP receptor activation is believed to provide additional benefits for weight management. GIP agonism can further enhance insulin release, improve glucose tolerance, and may have independent effects on appetite regulation.
When combined with GLP-1 receptor activation, the result is a more comprehensive effect on appetite control, glucose metabolism, and energy expenditure.
Clinical studies have shown that dual GIP and GLP-1 receptor agonist therapy can lead to greater reductions in body weight and improvements in metabolic health compared to single agonist treatments. This mechanism is the foundation for the observed clinical outcomes with tirzepatide injections.
Single agonist weight loss injections, such as those containing GLP-1 receptor agonists like semaglutide and liraglutide, act only on the GLP-1 pathway. These medications help with weight loss by increasing feelings of fullness, reducing appetite, and slowing gastric emptying.
Semaglutide and liraglutide have been widely prescribed in Singapore for medical weight management and are well established in clinical practice.
Tirzepatide, by contrast, is classified as a dual agonist injection because it activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. By engaging two metabolic pathways rather than one, tirzepatide delivers a broader and more comprehensive effect on appetite regulation, glucose control, and energy balance.
Clinical studies have demonstrated that dual agonist therapy with tirzepatide can result in greater weight reduction and improved metabolic outcomes compared to single agonist GLP-1 treatments such as semaglutide and liraglutide.
The dual mechanism of action is a key distinguishing feature, making tirzepatide a distinct option among injectable weight loss medications available in Singapore.
Tirzepatide’s role in medical weight management is supported by extensive clinical research. Multiple large-scale trials have examined its effectiveness, safety profile, and comparative outcomes against other weight loss injections such as semaglutide.
Tirzepatide’s weight loss efficacy has been studied in a series of global clinical trials known as the SURMOUNT program. SURMOUNT-1 and SURMOUNT-2 are the most notable, involving adults with obesity or overweight, with or without type 2 diabetes.
In SURMOUNT-1, participants treated with tirzepatide over 72 weeks experienced average weight reductions of up to 20.9% of their baseline body weight, depending on the dose used.
The SURMOUNT-2 study, which included individuals with type 2 diabetes, showed an average weight loss of up to 15.7%. These results are considered among the most substantial weight reductions reported for injectable weight loss medications to date.
References:
SURMOUNT-1 (Tirzepatide in Obesity Without Diabetes)
SURMOUNT-2 (Tirzepatide in Obesity With Type 2 Diabetes)
Most patients using tirzepatide injections for weight loss begin to see measurable results within the first 4 to 8 weeks of treatment, with maximum weight reduction typically observed by week 72 in clinical studies.
The amount of weight lost can vary based on the prescribed dose and individual response, but the majority of participants in studies achieved weight reductions exceeding 15% of their starting weight.
Comparative studies have shown that tirzepatide produces greater average weight loss than single agonist GLP-1 injections, such as semaglutide and liraglutide. For example, in head-to-head analyses, tirzepatide has been associated with higher percentages of total body weight lost compared to semaglutide.
The SURMOUNT-5 head-to-head clinical trial demonstrated that tirzepatide 15 mg resulted in an average body weight loss of 20.2% at 72 weeks, compared to 13.7% with semaglutide over the same period.
You can read the published results here
These findings support tirzepatide’s use as an option for adults seeking doctor-supervised injectable weight loss treatment in Singapore.
Tirzepatide dual agonist injections are intended for adults seeking medical weight management under the supervision of a qualified healthcare provider in Singapore. Patient suitability is determined by several factors, including body mass index (BMI), medical history, and individual treatment goals.
Tirzepatide is generally prescribed for adults with a BMI of 30 kg/m² or higher (classified as obesity), or 27 kg/m² or higher with at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or dyslipidemia.
Assessment of overall health status, history of cardiovascular disease, and risk factors is also important before starting treatment.
A thorough consultation is necessary to evaluate eligibility for tirzepatide injections. This includes a review of current medical conditions, previous weight loss attempts, current medications, and relevant blood tests.
Doctors may also consider the patient’s motivation, treatment expectations, and ability to comply with regular follow-up appointments.
Tirzepatide is not suitable for individuals with a history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or those with a known hypersensitivity to any of its components.
Caution is also advised in patients with a history of pancreatitis, severe gastrointestinal disease, or certain psychiatric disorders. Tirzepatide is not recommended during pregnancy or breastfeeding.
Tirzepatide dual agonist injections are provided as part of a structured medical weight management program in Singapore. The treatment process involves several key steps to ensure patient safety, effective weight reduction, and ongoing clinical support.
Before starting tirzepatide dual agonist weight loss injections in Singapore, patients undergo a comprehensive medical consultation. This includes assessment of weight, BMI, medical history, and baseline laboratory investigations. The doctor will review previous weight management efforts and discuss expected benefits and possible risks associated with tirzepatide therapy.
Tirzepatide is administered as a subcutaneous injection once weekly. Treatment starts at 2.5 mg per week and is gradually increased every four weeks: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, up to a maximum of 15 mg per week.
Dose titration is based on individual tolerability and clinical response, optimizing both safety and weight loss outcomes. Adjustments are made according to each patient’s needs.
Regular follow-up appointments are scheduled at the clinic in Singapore to monitor progress, assess dosing, and manage any potential side effects. Patients are encouraged to attend ongoing reviews to track weight, metabolic health, and overall response to tirzepatide injections.
For patients switching to tirzepatide from another weight loss injection, such as semaglutide or liraglutide, a tailored transition plan is developed by the doctor. This may involve a medication washout period or careful timing of injections to reduce the risk of side effects and support treatment continuity.
Tirzepatide dual agonist injections are generally well tolerated, but like all medications, they may cause side effects in some individuals.
Understanding the safety profile of tirzepatide is important for anyone considering this weight loss injection as part of a medical weight management program in Singapore.
The most frequently reported side effects of tirzepatide injections include gastrointestinal symptoms such as nausea, vomiting, diarrhoea, constipation, and abdominal discomfort.
These side effects are most common during the initial dose escalation phase and often become less pronounced as the body adjusts to the medication.
Other possible side effects include decreased appetite, fatigue, and mild injection site reactions such as redness or swelling.
Although uncommon, tirzepatide has been associated with rare but serious adverse effects. These include pancreatitis (inflammation of the pancreas), severe gastrointestinal disease, and possible allergic reactions.
There is also a theoretical risk of medullary thyroid carcinoma, as observed with other medications in the GLP-1 receptor agonist class. Individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 are generally advised not to use tirzepatide.
Caution is advised when considering tirzepatide for patients with certain health conditions. Tirzepatide is not recommended for use during pregnancy or breastfeeding, and its safety has not been established in children or adolescents.
Individuals with a history of pancreatitis, severe gastrointestinal disorders, or certain psychiatric illnesses should discuss potential risks and benefits with their doctor before starting tirzepatide therapy.
Tirzepatide dual agonist injections for weight loss are available in Singapore by prescription and should only be started under the supervision of a licensed medical professional.
At our clinic, patients receive a comprehensive assessment and ongoing clinical support from Dr Edwin Lim and his medical team throughout their tirzepatide weight management journey.
Tirzepatide is not available over the counter in Singapore. A doctor’s prescription is required, and therapy must be tailored to each patient’s health status.
Your doctor will conduct a thorough evaluation—including medical history, physical examination, and relevant laboratory tests—before recommending tirzepatide as part of a structured medical weight management program.
After the initial assessment, tirzepatide injections may be self-administered at home following proper instruction, or performed at the clinic under medical supervision if preferred.
Regular follow-up appointments are essential to monitor progress, review dosing, and address any side effects. Ongoing supervision ensures that tirzepatide treatment remains both safe and effective.
Doctor-led supervision is essential for the safe use of tirzepatide dual agonist injections in Singapore. Regular monitoring allows for prompt management of any adverse effects, timely dose adjustments, and ongoing lifestyle guidance. Patients are encouraged to attend all scheduled reviews and communicate any concerns throughout their treatment.
Sustaining weight loss after completing a tirzepatide dual agonist injection program is a key consideration for individuals in Singapore. Understanding long-term outcomes, maintenance strategies, and insights from clinical studies can help patients plan for lasting weight control.
Clinical data from the SURMOUNT‑4 study indicate that some weight regain typically occurs after discontinuing tirzepatide.
However, most participants maintained a significant reduction compared to their original baseline even after stopping treatment.
To support long-term weight maintenance, patients are encouraged to continue healthy dietary habits, regular exercise, and behavioral techniques introduced during therapy.
Ongoing support from healthcare providers can help reinforce these practices and address any weight regain early. Periodic check-ins with your doctor can guide appropriate management adjustments.
Continued medical monitoring after stopping tirzepatide injections is advised. Regular follow-up appointments in Singapore can help evaluate metabolic health, reinforce lifestyle strategies, and discuss further treatment options if needed.
Patients experiencing weight regain or health changes may consult their doctor about resuming tirzepatide or considering alternative interventions.
Finding the right clinic for dual agonist (GIP and GLP-1) weekly weight loss injections in Singapore is essential for safe, effective, and personalised medical care. When selecting a provider, patients should consider several key factors to ensure optimal results.
Look for clinics where weight management treatments are led by experienced doctors who are familiar with dual agonist injections, such as tirzepatide. Doctor supervision ensures that your eligibility is thoroughly assessed, dosing is appropriately titrated, and any side effects are promptly managed.
A reputable clinic should have experience administering the latest injectable weight loss medications, including dual agonist (GIP and GLP-1) therapies. Ask about the clinic’s approach to patient education, safety protocols, and ongoing follow-up to support long-term success.
Effective weight loss requires more than just medication. The best clinics offer comprehensive support, including tailored lifestyle advice, nutrition counselling, and regular monitoring. Ongoing reviews allow your doctor to adjust treatment as needed and address any challenges during your weight management journey.
If you are interested in dual agonist weight loss injections or want to discuss your options with a qualified medical team, schedule a consultation with our clinic.
Contact us to learn more about our doctor-led, evidence-based weight management programmes in Singapore.
What Is the Dual GIP and GLP-1 Weekly Injection Used for Weight Loss in Singapore?
The dual GIP and GLP-1 weekly injection used for weight loss in Singapore is known commercially as Mounjaro (tirzepatide). Mounjaro is a once-weekly injectable medication developed by Eli Lilly and approved for medical weight management. It acts on both GIP and GLP-1 receptors to reduce appetite, improve glucose control, and promote significant weight loss.
How Does the Latest Dual Agonist Injection for Weight Loss Compare to Other Treatments?
Mounjaro (tirzepatide) differs from earlier weight loss injections, such as Ozempic (semaglutide), Wegovy, and Saxenda (liraglutide), by targeting two metabolic pathways: GIP and GLP-1 receptors. This dual mechanism has been shown in clinical studies to produce greater average weight loss than single agonist treatments. In the SURMOUNT-5 trial, Mounjaro 15 mg resulted in 20.2% average body weight loss at 72 weeks, compared to 13.7% with semaglutide.
What Dosing Protocol Is Used for the Dual Agonist Weekly Weight Loss Injection?
Mounjaro (tirzepatide) is administered as a subcutaneous injection once weekly. The dosing protocol starts at 2.5 mg per week and increases every four weeks to 5 mg, 7.5 mg, 10 mg, 12.5 mg, and up to a maximum of 15 mg per week. Dose titration is adjusted based on tolerability and clinical response under doctor supervision.
How Soon Can I Expect to See Results With the Dual Agonist Injection?
With Mounjaro, most patients begin to see appetite changes and initial weight loss within the first 4–8 weeks. Clinical studies such as SURMOUNT-1 have shown progressive weight reduction over 72 weeks, with average losses exceeding 15–20% of baseline body weight, depending on the dose.
What Happens If I Stop the Dual Agonist Weekly Injection?
After discontinuing Mounjaro injections, some degree of weight regain is expected, as observed in the SURMOUNT-4 study. However, many patients retain a portion of their weight loss compared to their original baseline. Long-term lifestyle changes and regular medical follow-up are important for weight maintenance after stopping Mounjaro.
Can I Switch to the Dual Agonist Injection From Another Weight Loss Medication?
Yes, it is possible to switch to Mounjaro from other weight loss injections such as Ozempic, Wegovy, or Saxenda. Your doctor will determine the appropriate transition plan to minimize side effects and ensure optimal treatment continuity.
Is the Dual Agonist Weekly Injection Approved in Singapore?
Mounjaro (tirzepatide) is approved in Singapore for medical weight management and is available by prescription only. Treatment should be initiated and supervised by a qualified doctor with experience in medical weight loss programs.
Who Is Suitable for the Dual GIP and GLP-1 Weekly Weight Loss Injection?
Mounjaro is suitable for adults with a BMI of 30 kg/m² or higher, or 27 kg/m² or higher with weight-related health conditions such as type 2 diabetes or hypertension. Suitability is determined by a doctor based on individual medical history, risk factors, and weight loss goals.
Are There Any Side Effects With the Dual Agonist Weight Loss Injection?
Mounjaro can cause side effects, most commonly gastrointestinal symptoms like nausea, vomiting, diarrhoea, or constipation. These effects usually occur during dose escalation and tend to decrease over time. Less common but serious risks include pancreatitis and, rarely, thyroid-related conditions. Patients should report any severe or persistent symptoms to their doctor promptly.
How Much Does the Dual Agonist Weekly Weight Loss Injection Cost in Singapore?
The cost of Mounjaro injections in Singapore can vary depending on the prescribed dose and clinic. On average, the monthly price ranges from approximately $600 to $1,200 before GST. For the latest pricing and package options, please contact us.
Can the Dual Agonist Injection Be Combined With Other Weight Loss Methods?
Mounjaro is most effective when combined with healthy dietary habits, regular exercise, and ongoing medical supervision. Some patients may use Mounjaro in conjunction with other non-injectable weight loss strategies. Always consult your doctor before combining medications or therapies.
How Do I Start the Dual Agonist Weekly Injection in Singapore?
To begin treatment with Mounjaro in Singapore, schedule a consultation with a doctor experienced in medical weight management. After an initial assessment and confirmation of suitability, your doctor will provide detailed instructions for dosing, self-injection, and follow-up care.
Can the Dual Agonist Weekly Injection Be Used for Weight Loss Without Diabetes?
Yes, Mounjaro (tirzepatide) is approved for weight management in adults regardless of diabetes status. Clinical studies, such as SURMOUNT-1, specifically evaluated its use in individuals with obesity or overweight who do not have type 2 diabetes, demonstrating substantial weight loss results.
What Should I Do If I Miss a Dose of the Dual Agonist Weight Loss Injection?
If you miss a scheduled Mounjaro (tirzepatide) injection, administer the missed dose as soon as possible within four days. If more than four days have passed, skip the missed dose and continue with your next scheduled injection. Do not take two doses within three days of each other. If unsure, consult your doctor for guidance.
Is Ongoing Blood Test Monitoring Required With the Dual Agonist Injection?
During Mounjaro treatment, your doctor may recommend periodic blood tests to monitor metabolic parameters, such as blood glucose, cholesterol, and liver function. Ongoing monitoring helps ensure the safe and effective use of tirzepatide injections as part of a comprehensive weight management plan in Singapore.
How Long Can I Stay on the Dual Agonist Weekly Injection for Weight Loss?
The duration of Mounjaro (tirzepatide) treatment is individualized. Some patients may continue therapy long-term to maintain weight loss and metabolic benefits, while others may stop after reaching their target weight. Your doctor will discuss an appropriate treatment plan and adjust the duration based on your progress and health goals.
Are There Any Food or Drug Interactions With the Dual Agonist Injection?
Mounjaro (tirzepatide) has no significant food restrictions. However, your doctor should review all your current medications to minimize potential drug interactions, especially with other diabetes or weight loss treatments. Inform your doctor about all supplements and medicines you are taking.
Is There a Waiting List or Limited Supply for the Dual Agonist Injection in Singapore?
As demand for Mounjaro (tirzepatide) is high, there may be occasional waiting lists or supply fluctuations at some clinics in Singapore. For the latest updates on availability or to reserve your treatment slot, please contact us.
What Lifestyle Changes Should I Make While on the Dual Agonist Weekly Injection?
For optimal results with Mounjaro, patients are advised to adopt healthy dietary habits, increase physical activity, and address behavioral factors related to weight management. Your doctor or clinic team can provide specific lifestyle guidance tailored to your needs during treatment.
Can Mounjaro Be Used Together With Other Weight Loss Injections?
Combining Mounjaro (tirzepatide) with other injectable weight loss medications such as Ozempic, Wegovy, or Saxenda is generally not recommended. Dual therapy may increase the risk of side effects and has not been shown to improve efficacy. Always consult your doctor before making any changes to your medication regimen.
Are There Any Contraindications for the Dual Agonist Injection?
Mounjaro should not be used in patients with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or known hypersensitivity to tirzepatide or its components. Your doctor will evaluate your full medical history before prescribing this treatment.
Copyrights 2025 by Edwin Lim Medical Aesthetic Clinic Pte. Ltd.
